Press Releases
  Date Title and Summary View
May 17, 2006
Rockville, MD, May 17, 2006  MacroGenics, Inc., a privately-held biotechnology company developing therapeutics for autoimmune disorders, cancer, and infectious diseases, today announced that it has raised $45 million in a Series C financing round.  The financing, led by Ventures West, included new investment groups Cai...
Oct 19, 2005
ROCKVILLE, MD.  October 19th, 2005.  MacroGenics, Inc. today announced the grand opening of its recently completed cGMP manufacturing facility located in Rockville, Maryland. The Company celebrated the grand opening with over 70 invited guests, including members of the Maryland state government and Montgomery County governme...
Jul 18, 2005
ROCKVILLE, MARYLAND.  July 18, 2005.  MacroGenics, Inc. announced today the signing of an agreement with Tolerance Therapeutics, Inc. in which MacroGenics will acquire the intellectual property, materials, and know-how related to a promising anti-CD3 monoclonal antibody for the treatment of Type 1, or juvenile, diabetes and other autoi...
Jun 17, 2005
ROCKVILLE, MARYLAND.  June 17, 2005  MacroGenics, Inc. today announced the addition of R. Nelson Campbell and Ronald L. Wilder, M.D., Ph.D. to the companys senior management team, as well as the promotions of Ezio Bonvini, M.D. and Joseph Panigot.  Commenting on the recent additions, Dr. Scott Koenig, President and CEO of MacroGen...
Oct 19, 2004
For Immediate Release Rockville, MD, October 19, 2004  ROCKVILLE, Md., OCTOBER 19 -- OriGene Technologies Inc. and MacroGenics, Inc. announced today that the companies have entered into a license agreement for a cancer target initially identified with OriGene's HTP- Rapid-ScanTM technology. Macro...
Oct 15, 2004
For Immediate Release Rockville, MD, October 15, 2004  MacroGenics, Inc., a growing biotechnology company developing antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases, announced the completion of its Series B financing of $30.5M led by Alta Partners and ...
Apr 26, 2004
CONTACTS: For Neose Technologies, Inc. Robert I. Kriebel - Sr. VP & CFO (215) 315-9000 Barbara Krauter - Manager (215) 315-9000 ...
Oct 29, 2003
CONTACTS: For Genzyme Sally Curley (investors) (617) 591-7140 Dan Quinn (media) (617) 591-5849 ...
Sep 4, 2003
The Department of Health and Human Services (HHS) today announced that the University of Texas Medical Branch at Galveston (UTMB) is among eight institutions nationwide receiving grants totaling approximately $350 million over five years to establish Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE). T...
Jun 7, 2002
Rockville, MD and Dallas, TX, June 7, 2002:  MacroGenics, Inc., a biotechnology company with operations in both Rockville, MD and Seattle, WA, today announced the acquisition of Eliance Biotechnology, Inc., a private vaccine discovery company located in Dallas, TX, which was founded to exploit technology developed at The Universi...
Apr 1, 2002
Rockville, MD April 1, 2002 - MacroGenics, Inc., a biotechnology company that is developing immunotherapeutics for treating cancer and inflammatory diseases, announced two key appointments to the senior management team. Michael S. Richman, Senior Vice President at MedImmune, Inc., joined the company today as Executive...
Sep 25, 2001
Rockville, MD September 25, 2001 -- MacroGenics Inc., a newly formed biotechnology company focusing on the development of immunotherapeutics for the treatment of cancer and inflammatory diseases, announced the appointment today of Scott Koenig, M.D., Ph.D, as President and Chief Executive Officer. The company, whose sci...
Page: FirstPrevious ...
7
= add release to Briefcase

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close